These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27326326)

  • 1. Discovery of Piperazinylquinoline Derivatives as Novel Respiratory Syncytial Virus Fusion Inhibitors.
    Zheng X; Wang L; Wang B; Miao K; Xiang K; Feng S; Gao L; Shen HC; Yun H
    ACS Med Chem Lett; 2016 Jun; 7(6):558-62. PubMed ID: 27326326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extensive Multiple 2D-/3D-QSAR Modeling, Molecular Docking and Pharmacophoric Approaches for Piperazinylquinoline Derivatives as Respiratory Syncytial Virus Fusion Inhibitors.
    Purohit VP; Thorat BR; Mali SN; Wagh RR; Yamgar RS
    Recent Adv Antiinfect Drug Discov; 2023; 18(2):148-167. PubMed ID: 36424780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors.
    Zheng X; Liang C; Wang L; Wang B; Liu Y; Feng S; Wu JZ; Gao L; Feng L; Chen L; Guo T; Shen HC; Yun H
    J Med Chem; 2018 Nov; 61(22):10228-10241. PubMed ID: 30339388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Characterization of TP0591816, a Novel Macrocyclic Respiratory Syncytial Virus Fusion Inhibitor with Antiviral Activity against F Protein Mutants.
    Yoshida I; Arikawa K; Honma Y; Inatani S; Yoshinaga M; Sugiyama H
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
    Blockus S; Sake SM; Wetzke M; Grethe C; Graalmann T; Pils M; Le Goffic R; Galloux M; Prochnow H; Rox K; Hüttel S; Rupcic Z; Wiegmann B; Dijkman R; Rameix-Welti MA; Eléouët JF; Duprex WP; Thiel V; Hansen G; Brönstrup M; Haid S; Pietschmann T
    Antiviral Res; 2020 May; 177():104774. PubMed ID: 32197980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors.
    Feng S; Li C; Chen D; Zheng X; Yun H; Gao L; Shen HC
    Eur J Med Chem; 2017 Sep; 138():1147-1157. PubMed ID: 28772235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dichloro-Phenyl-Benzotriazoles: A New Selective Class of Human Respiratory Syncytial Virus Entry Inhibitors.
    Piras S; Sanna G; Carta A; Corona P; Ibba R; Loddo R; Madeddu S; Caria P; Aulic S; Laurini E; Fermeglia M; Pricl S
    Front Chem; 2019; 7():247. PubMed ID: 31041309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of Cross-Resistance to Fusion Inhibitors Conferred by the K394R Mutation in Respiratory Syncytial Virus Fusion Protein.
    Tang W; Li Y; Song Q; Wang Z; Li M; Zhang Q; Wang Y; Ye W; Li Y
    J Virol; 2021 Sep; 95(20):e0120521. PubMed ID: 34379500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Synthesis of 2-(1-Alkylaminoalkyl)pyrazolo[1,5-a]pyrimidines as New Respiratory Syncytial Virus Fusion Protein Inhibitors.
    Yamaguchi-Sasaki T; Tamura Y; Ogata Y; Kawaguchi T; Kurosaka J; Sugaya Y; Iwakiri K; Busujima T; Takahashi R; Ueda-Yonemoto N; Tanigawa E; Abe-Kumasaka T; Sugiyama H; Kanuma K
    Chem Pharm Bull (Tokyo); 2020; 68(4):345-362. PubMed ID: 32238652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection.
    Wang G; Deval J; Hong J; Dyatkina N; Prhavc M; Taylor J; Fung A; Jin Z; Stevens SK; Serebryany V; Liu J; Zhang Q; Tam Y; Chanda SM; Smith DB; Symons JA; Blatt LM; Beigelman L
    J Med Chem; 2015 Feb; 58(4):1862-78. PubMed ID: 25667954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
    Mackman RL; Sangi M; Sperandio D; Parrish JP; Eisenberg E; Perron M; Hui H; Zhang L; Siegel D; Yang H; Saunders O; Boojamra C; Lee G; Samuel D; Babaoglu K; Carey A; Gilbert BE; Piedra PA; Strickley R; Iwata Q; Hayes J; Stray K; Kinkade A; Theodore D; Jordan R; Desai M; Cihlar T
    J Med Chem; 2015 Feb; 58(4):1630-43. PubMed ID: 25574686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
    Perron M; Stray K; Kinkade A; Theodore D; Lee G; Eisenberg E; Sangi M; Gilbert BE; Jordan R; Piedra PA; Toms GL; Mackman R; Cihlar T
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1264-73. PubMed ID: 26666922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of N-Containing (-)-Borneol Esters as Respiratory Syncytial Virus Fusion Inhibitors.
    Sokolova AS; Yarovaya OI; Kuzminykh LV; Shtro AA; Klabukov AM; Galochkina AV; Nikolaeva YV; Petukhova GD; Borisevich SS; Khamitov EM; Salakhutdinov NF
    Pharmaceuticals (Basel); 2022 Nov; 15(11):. PubMed ID: 36422520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of 1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 1.
    Bond S; Draffan AG; Fenner JE; Lambert J; Lim CY; Lin B; Luttick A; Mitchell JP; Morton CJ; Nearn RH; Sanford V; Stanislawski PC; Tucker SP
    Bioorg Med Chem Lett; 2015 Feb; 25(4):969-75. PubMed ID: 25595682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A.
    Zhang GN; Li Q; Zhao J; Zhang X; Xu Z; Wang Y; Fu Y; Shan Q; Zheng Y; Wang J; Zhu M; Li Z; Cen S; He J; Wang Y
    Eur J Med Chem; 2020 Jan; 186():111861. PubMed ID: 31734025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium.
    Brookes DW; Coates M; Allen H; Daly L; Constant S; Huang S; Hows M; Davis A; Cass L; Ayrton J; Knowles I; Strong P; Rapeport G; Ito K
    Br J Pharmacol; 2018 Jun; 175(12):2520-2534. PubMed ID: 29579332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and anti-respiratory syncytial virus potential of novel 3-(1,2,3-triazol-1-yl)furoxazine-fused benzimidazole derivatives.
    Mao L; Wang S; Qu Y; Wang H; Zhao Y; Zhu C; Zhang Z; Jin C; Herdewijn P; Liu FW; Wang Z
    Eur J Med Chem; 2023 Dec; 261():115799. PubMed ID: 37722289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor.
    Zheng X; Gao L; Wang L; Liang C; Wang B; Liu Y; Feng S; Zhang B; Zhou M; Yu X; Xiang K; Chen L; Guo T; Shen HC; Zou G; Wu JZ; Yun H
    J Med Chem; 2019 Jul; 62(13):6003-6014. PubMed ID: 31194544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 3,3'-Spiro[Azetidine]-2-oxo-indoline Derivatives as Fusion Inhibitors for Treatment of RSV Infection.
    Shi W; Jiang Z; He H; Xiao F; Lin F; Sun Y; Hou L; Shen L; Han L; Zeng M; Lai K; Gu Z; Chen X; Zhao T; Guo L; Yang C; Li J; Chen S
    ACS Med Chem Lett; 2018 Feb; 9(2):94-97. PubMed ID: 29456794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis.
    Jacque E; Chottin C; Laubreton D; Nogre M; Ferret C; de Marcos S; Baptista L; Drajac C; Mondon P; De Romeuf C; Rameix-Welti MA; Eléouët JF; Chtourou S; Riffault S; Perret G; Descamps D
    Front Immunol; 2021; 12():683902. PubMed ID: 34163482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.